Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 11/20 | 0.45 |
| ▸ | BTK | Q06187 | 7/20 | 0.40 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | TEK | Q02763 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | TEC | P42680 | 1/20 | 0.38 |
| ▸ | BMX | P51813 | 1/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.38 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.38 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167514 | 0.93 | TNK2 (0.45) | TNK2BTKLCKKDRTEK | |
| SCHEMBL167516 | 0.93 | TNK2 (0.45) | TNK2BTKLCKKDRTEK | |
| SCHEMBL122860 | 0.91 | TNK2 (0.52) | TNK2BTKLCKKDRTEK | |
| SCHEMBL122968 | 0.91 | TNK2 (0.52) | TNK2BTKLCKKDRTEK | |
| SCHEMBL169877 | 0.91 | TNK2 (0.52) | TNK2BTKLCKKDRTEK | |
| SCHEMBL169875 | 0.91 | TNK2 (0.52) | TNK2BTKLCKKDRTEK | |
| SCHEMBL169911 | 0.89 | TNK2 (0.46) | TNK2BTKLCKKDRTEK | |
| SCHEMBL169912 | 0.89 | TNK2 (0.46) | TNK2BTKLCKKDRTEK | |
| SCHEMBL169792 | 0.86 | TNK2 (0.45) | TNK2BTKLCKKDRTEK | |
| SCHEMBL169231 | 0.86 | TNK2 (0.45) | TNK2BTKLCKKDRTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | claimed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | claimed |
| US-20140357636-A1 | Treatment of Skeletal-Related Disorders | ROTHBAUM WAYNE (US) | 2014-12-04 | — | — | US | disclosed |
| US-8765754-B2 | Pyrrolotriazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2424368-A1 | PYRROLOTRIAZINE COMPOUNDS | Locus Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126960-A1 | PYRROLOTRIAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357636-A1 | Treatment of Skeletal-Related Disorders | SOST, COL2A1, CYP27B1 | TNK2 1030/4885BTK 4374/4885LCK 4767/4885 |
| US-20120232054-A1 | PYRROLOTRIAZINE COMPOUNDS | BTK, SYK, ZAP70 | TNK2 511/4885BTK 1/4885LCK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.